MX2021001764A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2021001764A
MX2021001764A MX2021001764A MX2021001764A MX2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A
Authority
MX
Mexico
Prior art keywords
combination therapy
inhibitor
effective amount
kinase
methods
Prior art date
Application number
MX2021001764A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2021001764A publication Critical patent/MX2021001764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan métodos para tratar enfermedades como el cáncer usando una terapia de combinación. En ciertas formas de realización, los métodos comprenden administrar a un paciente una cantidad eficaz de un inhibidor de la fosfoinositido-3-quinasa (PI3K) y una cantidad eficaz de un inhibidor de la quinasa dependiente de ciclina (CDK).
MX2021001764A 2018-08-14 2019-08-13 Terapia de combinacion. MX2021001764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
MX2021001764A true MX2021001764A (es) 2021-04-19

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001764A MX2021001764A (es) 2018-08-14 2019-08-13 Terapia de combinacion.

Country Status (9)

Country Link
US (1) US20210161909A1 (es)
JP (1) JP2021534114A (es)
CN (1) CN112839651A (es)
AU (1) AU2019322858A1 (es)
EA (1) EA202190360A1 (es)
IL (1) IL280729A (es)
MX (1) MX2021001764A (es)
TW (1) TW202021592A (es)
WO (1) WO2020036995A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023167856A1 (en) * 2022-03-01 2023-09-07 Mei Pharma, Inc. Combination therapy of pi3k inhibitor and pd-1 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0621777A2 (pt) * 2006-06-21 2013-03-12 Piramal Life Sciences Ltd derivados de flavona enantiomericamente puros para o tratamento de distérbios proliferativos e processos para sua preparaÇço
WO2012135160A1 (en) * 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2016024232A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
CA3103604C (en) * 2016-03-28 2023-09-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
US20190201409A1 (en) * 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
MX2019013862A (es) * 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
CA3072476A1 (en) * 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy

Also Published As

Publication number Publication date
WO2020036995A1 (en) 2020-02-20
CN112839651A (zh) 2021-05-25
US20210161909A1 (en) 2021-06-03
EA202190360A1 (ru) 2021-07-15
TW202021592A (zh) 2020-06-16
AU2019322858A1 (en) 2021-04-01
IL280729A (en) 2021-03-25
JP2021534114A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
MX2020009773A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
MX2019003134A (es) Terapia de combinacion.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
SG10201902664RA (en) Combination therapy for treating cancer
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2019013862A (es) Terapia de combinacion.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
SG10201909199PA (en) Method for treating cancer
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021001764A (es) Terapia de combinacion.
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.